Aprogen Biologics Inc. (KRX:003060)
780.00
-6.00 (-0.76%)
At close: Mar 28, 2025, 3:30 PM KST
Aprogen Biologics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Net Income | -104,979 | -118,270 | 12,639 | 8,103 | 11,253 | Upgrade
|
Depreciation & Amortization | 19,090 | 21,398 | 2,404 | 2,072 | 1,932 | Upgrade
|
Loss (Gain) From Sale of Assets | -16.15 | 151,537 | -3.1 | -53.08 | -593.48 | Upgrade
|
Asset Writedown & Restructuring Costs | 154.08 | 2,271 | 264.15 | 2,134 | 241.5 | Upgrade
|
Loss (Gain) From Sale of Investments | 9,934 | -34,724 | -1,380 | -1,623 | -2,476 | Upgrade
|
Loss (Gain) on Equity Investments | 29,047 | -75,012 | -1,353 | -352.2 | -5,375 | Upgrade
|
Provision & Write-off of Bad Debts | 0.01 | -24.29 | -2,224 | -26.23 | -1,532 | Upgrade
|
Other Operating Activities | 16,980 | 31,164 | 1,476 | -720.21 | 5,844 | Upgrade
|
Change in Accounts Receivable | -2,217 | 1,218 | -637.92 | -494.75 | 902.78 | Upgrade
|
Change in Inventory | -5,708 | -3,284 | -1,180 | -1,023 | -1,606 | Upgrade
|
Change in Accounts Payable | 662.83 | -2,373 | 313.46 | -155.63 | 272.35 | Upgrade
|
Change in Income Taxes | - | - | - | - | 3.85 | Upgrade
|
Change in Other Net Operating Assets | 6,056 | -7,550 | 15,410 | -14,088 | -779.66 | Upgrade
|
Operating Cash Flow | -30,996 | -33,651 | 25,728 | -6,227 | 8,088 | Upgrade
|
Operating Cash Flow Growth | - | - | - | - | 1033.22% | Upgrade
|
Capital Expenditures | -15,264 | -28,088 | -1,284 | -796.19 | -976.29 | Upgrade
|
Sale of Property, Plant & Equipment | 16.53 | 16.82 | 16.36 | 66.71 | 51.07 | Upgrade
|
Cash Acquisitions | - | -9,223 | - | - | - | Upgrade
|
Divestitures | 200 | - | 3,074 | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -187.34 | -308.06 | -261.4 | -145.94 | -292.21 | Upgrade
|
Investment in Securities | -12,262 | -79,690 | 22,197 | 75,048 | -70,507 | Upgrade
|
Other Investing Activities | -24,225 | 22,086 | -76,742 | -97,329 | -123,544 | Upgrade
|
Investing Cash Flow | -51,722 | -95,206 | -53,001 | -23,156 | -195,268 | Upgrade
|
Short-Term Debt Issued | 53,950 | 49,610 | 20,500 | - | - | Upgrade
|
Long-Term Debt Issued | 39,997 | 114,611 | - | - | - | Upgrade
|
Total Debt Issued | 93,947 | 164,221 | 20,500 | - | - | Upgrade
|
Short-Term Debt Repaid | -60,650 | -122,110 | -4,000 | - | - | Upgrade
|
Long-Term Debt Repaid | -61,594 | -353.06 | -262.55 | -349.3 | -410.3 | Upgrade
|
Total Debt Repaid | -122,244 | -122,463 | -4,263 | -349.3 | -410.3 | Upgrade
|
Net Debt Issued (Repaid) | -28,297 | 41,758 | 16,237 | -349.3 | -410.3 | Upgrade
|
Issuance of Common Stock | 115,759 | 40,000 | 0.24 | - | 235,376 | Upgrade
|
Repurchase of Common Stock | -21.72 | -4,425 | - | - | - | Upgrade
|
Other Financing Activities | -2,468 | 37,957 | -455.34 | -0.96 | -13,262 | Upgrade
|
Financing Cash Flow | 84,972 | 115,289 | 15,782 | -350.26 | 221,704 | Upgrade
|
Foreign Exchange Rate Adjustments | - | 11.65 | 25.04 | 11.02 | -24.83 | Upgrade
|
Miscellaneous Cash Flow Adjustments | - | - | 0 | -0 | - | Upgrade
|
Net Cash Flow | 2,253 | -13,555 | -11,465 | -29,722 | 34,499 | Upgrade
|
Free Cash Flow | -46,261 | -61,739 | 24,444 | -7,023 | 7,112 | Upgrade
|
Free Cash Flow Margin | -68.66% | -70.67% | 37.50% | -12.43% | 13.34% | Upgrade
|
Free Cash Flow Per Share | -367.96 | -978.78 | 604.74 | -176.20 | 223.97 | Upgrade
|
Cash Interest Paid | 2,213 | 151.04 | 25.77 | 89.51 | 117.14 | Upgrade
|
Cash Income Tax Paid | -31.26 | -2,485 | 2,115 | 1,810 | 740.06 | Upgrade
|
Levered Free Cash Flow | -24,026 | 13,979 | 104,474 | -97,245 | -29,721 | Upgrade
|
Unlevered Free Cash Flow | -20,579 | 16,272 | 104,645 | -97,226 | -29,690 | Upgrade
|
Change in Net Working Capital | -12,392 | -67,451 | -106,414 | 95,871 | 29,678 | Upgrade
|
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.